

TOGETHER, WE CAN  
**ELIMINATE  
CERVICAL  
CANCER**

This resource was developed by IGCS with support from the University of Sydney team, led by Prof. Karen Canfell with a cut-off date of October 2025.

IGCS commits to updating this summary of key publications annually and will support a landscape analysis to update the resources available on [www.iccp-portal.org](http://www.iccp-portal.org) in Q4 each year. Share your suggestions for additions by emailing [igcs@igcs.org](mailto:igcs@igcs.org).

**This work is part of the IGCS Accelerating Cervical Cancer Elimination Strategies Symposia and 5-year project with the vision that:**


**By 2030, every high-burden country will have a national cervical cancer elimination strategy actively being implemented.**

## RECOMMENDED READING

**Peer-reviewed literature on cervical cancer elimination**



Global strategy to accelerate the elimination of cervical cancer as a public health problem



# The IGCS ACCESS Series is in alignment with The Global Strategy of WHO

Three pillars provide a comprehensive strategy for cervical cancer control to ensure that lifetime benefits are maintained, using life-course approach

**THRESHOLD:** All countries to reach < 4 cases per 100 000 women

## 2030 Control Targets

**90%**

of girls fully vaccinated with HPV vaccine by age 15 years.

**70%**

of women are screened with a high-performance test by 35 years of age and again by 45 years of age.

**90%**

of women identified with cervical disease receive treatment (90% of women with precancer treated, and 90% of women with invasive cancer managed).



## Must-Read Papers: Cross-pillar

	Topic	Title	Reference
Cross-pillar	<b>Achieving Cervical Cancer Elimination: the impact of the 3 pillars</b>	Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study	<a href="#">Simms KT, et al. The lancet oncology 2019; 20(3): 394-407.</a>
		Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries	<a href="#">Brisson M et.al. Lancet. 2020 PMID: 32007141.</a>
		Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries	<a href="#">Canfell K et.al. Lancet. 2020 PMID: 32007142.</a>
		Elimination of cervical cancer: the impact of HPV vaccination, primary HPV screening , and expanded access to cancer treatment services	<a href="#">Hall M, et.al. Molecular Aspects of Medicine</a>
	<b>Achieving Cervical Cancer Elimination: the impact of key economic, political, sociocultural, and health-system determinants</b>	Achieving cervical cancer elimination: an ecological assessment of global determinants using a policy determinant model.	<a href="#">Hyatt A et.al. The Lancet Global health 2025; 13(11): e1828-e36.</a>

## Must-Read Papers: Pillar 1 (HPV vaccination)

Topics	Title	Reference
<b>Efficacy of HPV vaccination</b>	Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis	<a href="#">Drolet M, et.al. Lancet 2019; 394(10197): 497-509.</a>
	HPV Vaccination and the Risk of Invasive Cervical Cancer	<a href="#">Lei J, et.al. N Engl J Med. 2020. PMID: 32997908.</a>
<b>HPV vaccine: 1-dose schedule</b>	Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results	<a href="#">KEN SHE trial (Kenya): Barnabas RV, et al. Nat Med 2023; 29(12): 3224-32.</a>
	HPV16/18 antibodies 16-years after single dose of bivalent HPV vaccination: Costa Rica HPV vaccine trial	<a href="#">Costa Rica Vaccine Trial (CVT): Porras C, et.al. J Natl Cancer Inst Monogr. 2024; PMID: 39529529.</a>
	A prospective cohort study comparing efficacy of 1 dose of quadrivalent human papillomavirus vaccine to 2 and 3 doses at an average follow up of 12 years postvaccination	<a href="#">IARC India Trial: Malvi SG, et.al. J Natl Cancer Inst Monogr. 2024. PMID: 39529521.</a>
	Evidence for an HPV one-dose schedule	<a href="#">Stanley M, Schuind A, Muralidharan KK, et al. Evidence for an HPV one-dose schedule. Vaccine 2024; 42 Suppl 2: S16-s21.</a>
	Durability of immunogenicity at 5 years after a single dose of human papillomavirus vaccine compared with two doses in Tanzanian girls aged 9-14 years: results of the long-term extension of the DoRIS randomised trial.	<a href="#">DoRIS (Tanzania) Trial: Watson-Jones D, et.al. Lancet Glob Health. 2025; PMID: 39890232.</a>
<b>New vaccine - prequalified for single dose</b>	Long-term efficacy and immunopersistence of an Escherichia coli-produced HPV-16/18 bivalent vaccine: an observational extension study following a randomised, double-blind Phase III clinical trial cohort	<a href="#">Zhao F, et al. Lancet Reg Health West Pac 2025; 61: 101668.</a>

# Must-Read Papers: Pillar 2 (Cervical Screening with a High-Performance Test)

	Topics	Title	Reference
Pillar 2	Cervical cancer screening from the IARC perspective	The IARC Perspective on Cervical Cancer Screening	<a href="#">Bouvard V, et.al. N Engl J Med. 2021; PMID: 34758259.</a>
	Impact of HPV screening on cervical cancer risk	Human papillomavirus-based cervical screening and long-term cervical cancer risk: a randomised health-care policy trial in Sweden	<a href="#">Wang J, et.al. Lancet Public Health. 2024. PMID: 39486904.</a>
	Effectiveness and cost-effectiveness of screening – Evidence from modelled evaluation	Benefits, harms and cost-effectiveness of cervical screening, triage and treatment strategies for women in the general population.	<a href="#">Simms KT, et.al. Nat Med. 2023 PMID: 38087115.</a>
		Benefits and harms of cervical screening, triage and treatment strategies in women living with HIV	<a href="#">Hall MT, et.al. Nat Med. 2023 PMID: 38087116.</a>
	Effectiveness of HPV screening – Evidence from population-based studies	HPV screening for cervical cancer in rural India	<a href="#">Sankaranarayanan R, et.al. N Engl J Med. 2009; PMID: 19339719.</a>
		Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial	<a href="#">Denny L, et.al. J Natl Cancer Inst. 2010; PMID: 20884893.</a>
		Point-of-care HPV DNA testing of self-collected specimens and same-day thermal ablation for the early detection and treatment of cervical pre-cancer in women in Papua New Guinea: a prospective, single-arm intervention trial (HPV-STAT)	<a href="#">Vallely AJB, et.al. Lancet Glob Health. 2022; PMID: 35878625.</a>
		Performance of cervical cytology and HPV testing for primary cervical cancer screening in Latin America: an analysis within the ESTAMPA study	<a href="#">Ramírez AT, et.al; ESTAMPA Study Group. Lancet Reg Health Am. 2023 PMID: 37766799.</a>
	Accuracy of HPV self-collection	Collaboration on Self-Sampling and HPV Testing. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses	<a href="#">Arbyn M, et.al. BMJ. 2018. PMID: 30518635.</a>
	Inventory of HPV tests, including clinically validated	2023 global inventory of commercial molecular tests for human papillomaviruses (HPV)	<a href="#">Poljak M, et.al. J Clin Virol. 2024. PMID: 38518504.</a>

## Must-read Papers: Pillar 3 (Treatment and Palliative Care)

	Topics	Title	Reference
Pillar 3	Review paper	Cervical cancer	<a href="#">Tewari KS. N Engl J Med. 2025</a>
	Cervical cancer treatment in women living with HIV	Cervical cancer treatment outcomes and survival in Botswana by human immunodeficiency virus status: Ipabalele study results	<a href="#">Grover S, et.al. JNCI Cancer Spectr. 2025. PMID: 40342166.</a>
	Surgery and Radiotherapy	Benchmarking of the Cervical Cancer Care Cascade and Survival Outcomes After Radiation Treatment in a Low- and Middle-Income Country Setting	<a href="#">Grover S, et.al. JCO Glob Oncol. 2023. PMID: 37738538.</a>
		Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer	<a href="#">Plante M, et.al. N Engl J Med. 2024; PMID: 38416430.</a>
	Palliative Care	Cervical Cancer-Associated Suffering: Estimating the Palliative Care Needs of a Highly Vulnerable Population	<a href="#">Krakauer EL, et.al. JCO Glob Oncol. 2021. PMID: 34115522.</a>
		Essential Package of Palliative Care for Women With Cervical Cancer: Responding to the Suffering of a Highly Vulnerable Population	<a href="#">Krakauer EL, et.al. JCO Glob Oncol. 2021. PMID: 34115527.</a>
		Augmented Package of Palliative Care for Women With Cervical Cancer: Responding to Refractory Suffering	<a href="#">Krakauer EL, et.al. JCO Glob Oncol. 2021. PMID: 34115537.</a>